Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit In Resected Head & Neck Cancers Oncology Times - OncTimes Talk podcast

Artwork

Medicine Oncology Cancer Oncology Times Science News Health and Well-Being

Innhold levert av Oncology Times. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncology Times eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Oncology Times - OncTimes Talk « »
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers

5M ago 13:00

Del

Innhold levert av Oncology Times. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncology Times eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in some patients.

At the AACR Annual Meeting 2024, Olivier Lantz, MD, PhD, Head of the Clinical Immunology Laboratory at the Institut Curie Hospital in Paris, reported data using a “neoantigen-based vaccine” specifically designed to recognize multiple genetic features unique to each patient’s tumor. During the conference, Lantz called into the OncTimesTalk studio to tell Peter Goodwin about the clinical options that could develop from such highly personalized vaccines.

… continue reading

159 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Artwork

Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers

Oncology Times - OncTimes Talk

22 subscribers

published 5M ago

Del

Innhold levert av Oncology Times. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Oncology Times eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in some patients.

At the AACR Annual Meeting 2024, Olivier Lantz, MD, PhD, Head of the Clinical Immunology Laboratory at the Institut Curie Hospital in Paris, reported data using a “neoantigen-based vaccine” specifically designed to recognize multiple genetic features unique to each patient’s tumor. During the conference, Lantz called into the OncTimesTalk studio to tell Peter Goodwin about the clinical options that could develop from such highly personalized vaccines.

… continue reading

159 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Alle episoder

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema